Pionyr Immunotherapeutics

Pionyr (formerly Precision Immune) is developing cancer immunotherapies targeting the tumor microenvironment to enhance the body's anti-tumor immunity. The company’s Myeloid Tuning technology is based on the knowledge that the tumor microenvironment can be altered by selectively changing the cellular infiltration in a way that favors immune-activating cells over immune-suppressive cells, thereby enhancing the immune system's defense against cancer, particularly when used in combination with checkpoint inhibitors.